<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Biochemical Engineering</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name><gtr:address><gtr:line1>BBSRC</gtr:line1><gtr:line2>Polaris House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1UH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A8ACADD2-6AB0-4C00-BE1E-C69D90DBBE5A"><gtr:id>A8ACADD2-6AB0-4C00-BE1E-C69D90DBBE5A</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:otherNames>Gilbert</gtr:otherNames><gtr:surname>Bracewell</gtr:surname><gtr:orcidId>0000-0003-3866-3304</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FE21E034-520F-4046-BE23-34A2E7948AB5"><gtr:id>FE21E034-520F-4046-BE23-34A2E7948AB5</gtr:id><gtr:firstName>Gary</gtr:firstName><gtr:surname>Lye</gtr:surname><gtr:orcidId>0000-0002-6018-2091</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FM017222%2F1"><gtr:id>FAC9DA6D-B3E5-4A27-B113-B7001DEE3839</gtr:id><gtr:title>Nanofibre scale-up and industrial validation - Industrial Biotechnology Catalyst Translation and Industrial Research Awards</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/M017222/1</gtr:grantReference><gtr:abstractText>Biopharmaceuticals are an increasingly important sector of the pharmaceutical industry, over one third of all drugs now in development are biopharmaceuticals and they make up half of the top 10 revenue blockbusters. It typically takes over 10 years and $800 million to develop a new drug. Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer and neurodegenerative conditions, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies now used to ensure the safety and efficacy of these treatments. This project aims to build on existing collaborations between Puridify, an SME with a novel nanofibre purification technology, and University College London (UCL), a world leading research organisation for the development of industrial bioprocessing technologies. The successful award of this project lead by Puridify and supported by shadow industrial partners will see the development and commercialisation of innovative bioprocessing platform technologies allowing the cost effective manufacture of a wide range of existing and new products.

The project will accelerate development of Puridify's novel platform downstream bioprocessing technologies towards commercial activity. The technologies increased productivity will provide an efficient manufacturing route to both new and existing products benefiting society and the sector as a whole by reducing costs and enabling the economic manufacture of next generation biotherapeutics. Using new processing technologies, theory and modelling, this integrated Industrial Research and Development project will accelerate the commercialisation of this technology by bringing together key academic and business components of the UK Industrial Biotechnology community.</gtr:abstractText><gtr:fund><gtr:end>2017-03-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2015-03-30</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>608611</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>This exploitation is supported by the original patent application (PCT/GB2012/052768) and a new patent application filed during this project (PCT/GB2013/052626). An on-going IP strategy to build and further protect future commercialisation opportunities is structured and continually evolving based on the development work that is being carried out.</gtr:description><gtr:firstYearOfImpact>2013</gtr:firstYearOfImpact><gtr:id>8C07425E-D8BE-4807-893F-2B0118BFC1B3</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56be1671a78483.93449141</gtr:outcomeId><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Biopharmaceuticals are an increasingly important sector of the pharmaceutical industry, over one third of all drugs now in
development are biopharmaceuticals and they make up half of the top 10 revenue blockbusters. It typically takes over 10
years and $800 million to develop a new drug. Global demand for cheaper biotherapeutics, which represent many of the
new tools in the fight against diseases such as cancer and neurodegenerative conditions, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies now used to ensure the safety and efficacy of these treatments. This project aims to build on existing collaborations between Puridify, an SME with a novel nanofibre purification technology, and University College London (UCL), a world leading research organisation
for the development of industrial bioprocessing technologies. The successful award of this project lead by Puridify and
supported by shadow industrial partners will see the development and commercialisation of innovative bioprocessing
platform technologies allowing the cost effective manufacture of a wide range of existing and new products.
The project will accelerate development of Puridify's novel platform downstream bioprocessing technologies towards
commercial activity. The technologies increased productivity will provide an efficient manufacturing route to both new and
existing products benefiting society and the sector as a whole by reducing costs and enabling the economic manufacture of
next generation biotherapeutics. Using new processing technologies, theory and modelling, this integrated Industrial
Research and Development project will accelerate the commercialisation of this technology by bringing together key
academic and business components of the UK Industrial Biotechnology community.</gtr:description><gtr:exploitationPathways>Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer and neurodegenerative conditions, drives the need for a reduction in manufacturing costs. A significant proportion of current costs arise from the purification technologies now used to ensure the safety and efficacy of these treatments. This project aims to build on existing collaborations between Puridify, an SME with a novel nanofibre purification technology, and University College London (UCL), a world leading research organisation for the development of industrial bioprocessing technologies. The successful award of this project lead by Puridify and supported by shadow industrial partners will see the development and commercialisation of innovative bioprocessing platform technologies allowing the cost effective manufacture of a wide range of existing and new products.</gtr:exploitationPathways><gtr:id>F90F994D-D77C-44B4-AC2A-3944DAE8269D</gtr:id><gtr:outcomeId>56be158a1fa652.17929793</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Puridify</gtr:companyName><gtr:description>Puridify's technology, FibroSelect - a novel chromatography reagent, offers significant advantages across key performance attributes that not only allow chromatography associated costs to be reduced by up to 90% but are also well aligned to meet the industry demands today and as the market evolves.</gtr:description><gtr:id>18B76133-BBCF-4C08-AB72-61B929C748D0</gtr:id><gtr:impact>Puridify have proven at research scale (0.2mL reagent) that their technology can operate at 50x throughput due to better permeability and fast mass transfer. This improves process economics by increasing productivity and is also beneficial when processing labile products. The reagent has shown better resistance than our competitors to impurity fouling and cleaning steps, a common cause of performance degradation over multiple cycles. The technology allows cheap and rapid bioprocess development due to uniform performance at all scales, promoting its adoption in industry.</gtr:impact><gtr:outcomeId>5416ffa592e251.20367268</gtr:outcomeId><gtr:url>http://puridify.com/</gtr:url><gtr:yearCompanyFormed>2013</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>520C82F9-79FD-427A-B7B8-3F254D904C5D</gtr:id><gtr:title>Nanofiber adsorbents for high productivity continuous downstream processing.</gtr:title><gtr:parentPublicationTitle>Journal of biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f98cd3ef65d3948e6ae5b0ebd16ecf77"><gtr:id>f98cd3ef65d3948e6ae5b0ebd16ecf77</gtr:id><gtr:otherNames>Hardick O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-1656</gtr:issn><gtr:outcomeId>563fbdd665a4f4.82741242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D4D0289-94F6-4BCD-BFB3-C261EC2C7FDD</gtr:id><gtr:title>Fabricating electrospun cellulose nanofibre adsorbents for ion-exchange chromatography.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ebdb10fafb8315bcf2ed72e7ab10f8c"><gtr:id>0ebdb10fafb8315bcf2ed72e7ab10f8c</gtr:id><gtr:otherNames>Dods SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9673</gtr:issn><gtr:outcomeId>563fbdd68ed8a9.58094839</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/M017222/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>17F21DBC-4946-4262-AD07-9914F6EA12F7</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Bioengineering</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>FA25733D-A456-4A1B-9D5C-7119577368D9</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Manufacturing</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>99E0B904-CAB5-4511-AFB3-AA6D2B171F97</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Process engineering</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>BD108981-2A72-4C45-AAC2-425461EB90BE</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Biomaterials</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>9C387DA5-CD5F-43E4-AA74-82CBF4DB6617</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Bioprocess Engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>86C61AF7-DC51-4A18-9679-D0EFD3860BFF</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Design of Process systems</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>ABBD3B7F-5022-4513-82D6-5414B965FAB3</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Manufacturing Machine &amp; Plant</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>